Charles Tuan-Tu Nguyen, MD
Psychiatry · Irvine, CANPI 1942380118
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,688,444 of the $2,136,611 with a category attached, or 79.0%. 23 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 44.8% of the total. 2025 is the largest year on record at $580,474, 3.4 times the $169,814 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,973 payments — averaging $718.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$957K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$537K
- Neurocrine Biosciences, Inc.$357K
- Axsome Therapeutics, Inc.$219K
- E.r. Squibb & Sons, L.L.C.$59K
- Sunovion Pharmaceuticals Inc.$2K
- plus $6K from 17 others
What the payments were for
- Consulting fees$199,2449%
- Speaking & faculty fees$1,688,44479%
- Travel & lodging$189,6999%
- Food & beverage$59,1413%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1,458 | $957,372 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 604 | $536,865 |
| Neurocrine Biosciences, Inc. | 370 | $356,713 |
| Axsome Therapeutics, Inc. | 236 | $219,035 |
| E.r. Squibb & Sons, L.L.C. | 79 | $59,067 |
| Sunovion Pharmaceuticals Inc. | 63 | $1,761 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 19 | $1,571 |
| Alkermes, Inc. | 34 | $1,279 |
| AbbVie(2 entities) | 53 | $758 |
| Teva Pharmaceuticals USA, Inc. | 12 | $700 |
| Vanda Pharmaceuticals Inc. | 18 | $406 |
| Indivior Inc. | 7 | $234 |
| Lundbeck LLC | 6 | $216 |
| Lilly USA, LLC | 3 | $186 |
| Bioxcel Therapeutics, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $123 |
| Noven Therapeutics, LLC | 3 | $55 |
| Biogen | 1 | $47 |
| Noven Pharmaceuticals, Inc. | 1 | $39 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,136,611 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 120 | $386,637 |
| IngrezzaValbenazine Tosylate | 34 | $277,313 |
| Abilify AsimtufiiAripiprazole | 34 | $195,631 |
| Abilify MaintenaAripiprazole | 28 | $77,394 |
| RexultiBrexpiprazole | 48 | $71,452 |
| CaplytaLumateperone Tosylate | 30 | $48,509 |
| Aripiprazole OdtAripiprazole | 44 | $41,259 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,600 |
| Divalproex Sodium | 363 | $15,350 |
| TrintellixVortioxetine Hydrobromide | 31 | $14,493 |
| Chlorpromazine Hcl | 59 | $13,794 |
| Aripiprazole | 177 | $8,538 |
| Quetiapine Fumarate | 521 | $7,422 |
| Haloperidol | 150 | $6,612 |
| Olanzapine OdtOlanzapine | 60 | $6,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $12 | $386,637120 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti | $957,372 | $344,476110 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $356,713 | $277,31334 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $536,865 | $48,50930 claims |
| Alkermes, Inc.Lybalvi | $1,279 | $22,60014 claims |
| Lilly USA, LLCOlanzapine | $186 | $5,709449 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Irvine
- Jason KelloggIrvine$2.7M
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jonathan MeyerSan Diego$2.3M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
- Jason BermakSan Rafael$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.